Avidity Stock Soars 36% on Collaboration Deal With Bristol Myers

Dow Jones2023-11-28

Avidity Biosciences stock was surging Tuesday after the biopharmaceutical company announced a licensing and research deal with Bristol Myers Squibb.

Avidity stock was soaring 36% to $8.39 in premarket trading Tuesday. Coming into the session, the stock has tumbled 72% this year.

As a part of the collaboration that is focused on the development and commercialization of multiple cardiovascular drugs, Bristol Myers will pay Avidity $60 million in cash and will also purchase about $40 million of Avidity common stock at $7.88 a share.

Avidity will also be eligible to receive up to around $1.35 billion in research and development milestone payments and up to about $825 million in commercial milestone payments. The company will also be eligible to receive royalties up to low double-digits of net sales.

"This collaboration with Avidity represents an important part of our continued investment in innovative therapeutic approaches that have the potential to provide transformative outcomes to patients living with serious cardiovascular conditions," Francisco Ramírez-Valle, head of the Immunology and Cardiovascular Thematic Research Center at Bristol Myers said in the news release.

Shares of Bristol Myers were up 0.5% to $49.27. Coming into the session, the stock has fallen 32% this year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

4

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2386411733?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-11-28 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2386411733","market":"us","top_or_hot":-1,"title":"Avidity Stock Soars 36% on Collaboration Deal With Bristol Myers","media":"Dow Jones","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences</a> stock was surging Tuesday after the biopharmaceutical company announced a licensing and research deal with Bristol Myers Squibb.</p><p>Avidity stock was soaring 36% to $8.39 in premarket trading Tuesday. Coming into the session, the stock has tumbled 72% this year.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9fe7b3b89c844eb3a77ca4a3f6b68dab\" tg-width=\"783\" tg-height=\"625\"/></p><p>As a part of the collaboration that is focused on the development and commercialization of multiple cardiovascular drugs, Bristol Myers will pay Avidity $60 million in cash and will also purchase about $40 million of Avidity common stock at $7.88 a share.</p><p>Avidity will also be eligible to receive up to around $1.35 billion in research and development milestone payments and up to about $825 million in commercial milestone payments. The company will also be eligible to receive royalties up to low double-digits of net sales.</p><p>&#34;This collaboration with Avidity represents an important part of our continued investment in innovative therapeutic approaches that have the potential to provide transformative outcomes to patients living with serious cardiovascular conditions,&#34; Francisco Ramírez-Valle, head of the Immunology and Cardiovascular Thematic Research Center at Bristol Myers said in the news release.</p><p>Shares of Bristol Myers were up 0.5% to $49.27. Coming into the session, the stock has fallen 32% this year.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avidity Stock Soars 36% on Collaboration Deal With Bristol Myers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvidity Stock Soars 36% on Collaboration Deal With Bristol Myers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-28 21:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Avidity Biosciences stock was surging Tuesday after the biopharmaceutical company announced a licensing and research deal with Bristol Myers Squibb.Avidity stock was soaring 36% to $8.39 in premarket ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RNA","symbol_name":"Avidity Biosciences, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2386411733","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2386411733","pubTimestamp":1701176895,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Avidity Biosciences stock was surging Tuesday after the biopharmaceutical company announced a licensing and research deal with Bristol Myers Squibb.Avidity stock was soaring 35% to $8.31 in premarket trading Tuesday. Coming into the session, the stock has tumbled 72% this year.As a part of the collaboration that is focused on the development and commercialization of multiple cardiovascular drugs, Bristol Myers will pay Avidity $60 million in cash and will also purchase about $40 million of Avidity common stock at $7.88 a share.Avidity will also be eligible to receive up to around $1.35 billion in research and development milestone payments and up to about $825 million in commercial milestone payments. The company will also be eligible to receive royalties up to low double-digits of net sales.\"This collaboration with Avidity represents an important part of our continued investment in innovative therapeutic approaches that have the potential to provide transformative outcomes to patients","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RNA":"Avidity Biosciences, Inc.","BMY":"施贵宝"},"translate_title":"与百时美施贵宝达成合作协议，Avidity股价飙升36%","themeId":"c5bbfdf5f7964880af97c1d6f417052c","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":0.9,"RNA":0.9},"content_text":"Avidity Biosciences stock was surging Tuesday after the biopharmaceutical company announced a licensing and research deal with Bristol Myers Squibb.Avidity stock was soaring 36% to $8.39 in premarket trading Tuesday. Coming into the session, the stock has tumbled 72% this year.As a part of the collaboration that is focused on the development and commercialization of multiple cardiovascular drugs, Bristol Myers will pay Avidity $60 million in cash and will also purchase about $40 million of Avidity common stock at $7.88 a share.Avidity will also be eligible to receive up to around $1.35 billion in research and development milestone payments and up to about $825 million in commercial milestone payments. The company will also be eligible to receive royalties up to low double-digits of net sales.\"This collaboration with Avidity represents an important part of our continued investment in innovative therapeutic approaches that have the potential to provide transformative outcomes to patients living with serious cardiovascular conditions,\" Francisco Ramírez-Valle, head of the Immunology and Cardiovascular Thematic Research Center at Bristol Myers said in the news release.Shares of Bristol Myers were up 0.5% to $49.27. Coming into the session, the stock has fallen 32% this year.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2386411733"}